Archives for 

patent dance

Supreme Court Oral Argument in Sandoz v. Amgen

Amgen v. Sandoz (filgrastim)  •  Approved Biosimilar Products  •  Biologics Litigation  •  Biosimilar News  •  BPCIA and Related U.S. Statutes  •  Patent Dance  •  U.S. Biosimilar Litigation News  •  U.S. Federal Circuit Decisions
The Supreme Court held a 70-minute oral argument in Sandoz v. Amgen this morning. Before beginning the argument, the Chief Justice announced that the Court would give each side five extra minutes–a highly unusual step reflecting […]

View More

Summary of Amgen’s Opening and Responsive Brief in Sandoz v. Amgen

Amgen v. Sandoz (filgrastim)  •  Approved Biosimilar Products  •  Biosimilar News  •  BPCIA and Related U.S. Statutes  •  Patent Dance  •  U.S. Biosimilar Litigation News  •  U.S. Federal Circuit Decisions
On Friday, March 10, Amgen filed its consolidated opening and responsive brief to the Supreme Court in Sandoz v. Amgen.  As we covered in a previous post, Sandoz filed its opening brief in the case […]

View More

Supreme Court Announces Briefing Schedule in Amgen v. Sandoz

Amgen v. Sandoz (pegfilgrastim)  •  BPCIA and Related U.S. Statutes  •  Patent Dance  •  U.S. Biosimilar Litigation News  •  U.S. Supreme Court Decisions
The Supreme Court has ordered a briefing schedule in Amgen v. Sandoz. Because the Court granted and consolidated Sandoz’s petition and Amgen’s conditional cross-petition, the Court has adopted a four-brief schedule, comparable to […]

View More

Year in Review: The Top-Five Legal Developments of 2016

Amgen v. Apotex (pegfilgrastim)  •  Amgen v. Sandoz (filgrastim)  •  Biosimilar News  •  BPCIA and Related U.S. Statutes  •  Patent Dance  •  PTAB + IPR  •  Reimbursement  •  Reimbursement  •  U.S. Biosimilar Litigation News  •  U.S. Federal Circuit Decisions  •  U.S. Supreme Court Decisions
Here are our picks for the top-five most significant legal developments in the world of biosimilars in 2016: 5) Congress passed and President Obama signed the 21st Century Cures Act.  Among other things, […]

View More

Breaking News: Apotex Does not Infringe Amgen’s Filgrastim and Pegfilgrastim Patent; Apotex is Permanently Enjoined From Launch Until It Provides 180 Days’ Notice

Amgen v. Apotex (pegfilgrastim)  •  Patent Dance  •  U.S. District Court Decisions
The District Court for the Southern District of Florida today ruled that Apotex’s proposed filgrastim and pegfilgrastim products will not infringe the asserted claims of Amgen’s ’138 patent (U.S. Patent. No. 8,952,138).  The court, […]

View More

Litigation Update: Motions in Janssen v. Celltrion for Entry of Final Judgment and Case Scheduling

Amgen v. Hospira (epoetin alfa)  •  Biosimilar News  •  BPCIA and Related U.S. Statutes  •  Janssen v. Celltrion (infliximab)  •  Patent Dance  •  U.S. Biosimilar Litigation News  •  U.S. District Court Decisions
  As we posted previously, the District Court in Janssen v. Celltrion has ruled that the ‘471 patent is invalid for obviousness-type double patenting on the two grounds raised in the defendants’ motions for summary judgment on that […]

View More